Trials / Terminated
TerminatedNCT04409223
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
A Phase III, Open Label, Randomised，Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib capsules | Oral KIT/PDGFRA kinase inhibitor |
| DRUG | Sunitinib Capsules | Oral receptor tyrosine kinase (RTK) inhibitor |
Timeline
- Start date
- 2020-09-12
- Primary completion
- 2022-03-25
- Completion
- 2022-03-25
- First posted
- 2020-06-01
- Last updated
- 2024-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04409223. Inclusion in this directory is not an endorsement.